Photosensitive drug eruption induced by bicalutamide within the UVB action spectrumSASADA, Kumiko; SAKABE, Jun-Ichi; TAMURA, Aiko et al.EJD. European journal of dermatology. 2012, Vol 22, Num 3, pp 402-403, issn 1167-1122, 2 p.Article

Eosinophilic lung disease induced by bicalutamide : A case report and review of the medical literatureWONG, P. W; MACRIS, N; DIFABRIZIO, L et al.Chest. 1998, Vol 113, Num 2, pp 548-550, issn 0012-3692Article

Bicalutamide: Clinical pharmacokinetics and metabolismCOCKSHOTT, Ian D.Clinical pharmacokinetics. 2004, Vol 43, Num 13, pp 855-878, issn 0312-5963, 24 p.Article

Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN : findings in repeat biopsies at 6 monthsBONO, Aldo V; MAZZUCCHELLI, Roberta; FERRARI, Ilaria et al.Journal of clinical pathology. 2007, Vol 60, Num 4, pp 443-446, issn 0021-9746, 4 p.Article

Effects of the anti-androgen, bicalutamide, in a reduced life-cycle study with the fathead minnow (Pimephales promelas)PANTER, G. H; GLENNON, Y. C; ROBINSON, J et al.Aquatic toxicology. 2012, Vol 114-15, pp 31-38, issn 0166-445X, 8 p.Article

Understanding the Performance of Melt-Extruded Poly(ethylene oxide)―Bicalutamide Solid Dispersions: Characterisation of Microstructural Properties Using Thermal, Spectroscopic and Drug Release MethodsABU-DIAK, Osama A; JONES, David S; ANDREWS, Gavin P et al.Journal of pharmaceutical sciences. 2012, Vol 101, Num 1, pp 200-213, issn 0022-3549, 14 p.Article

Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamideAXCRONA, Karol; AALTOMAA, Sirpa; DA SILVA, Carlos Martins et al.BJU international (Papier). 2012, Vol 110, Num 11, pp 1721-1728, issn 1464-4096, 8 p.Article

Phase II trial of RAD001 and bicalutamide for castration―resistant prostate cancerNAKABAYASHI, Mari; WERNER, Lilian; KANTOFF, Philip W et al.BJU international (Papier). 2012, Vol 110, Num 11, pp 1729-1735, issn 1464-4096, 7 p.Article

Physicochemical Characterization of Hot Melt Extruded Bicalutamide-Polyvinylpyrrolidone Solid DispersionsANDREWS, Gavin P; ABUDIAK, Osama A; JONES, David S et al.Journal of pharmaceutical sciences. 2010, Vol 99, Num 3, pp 1322-1335, issn 0022-3549, 14 p.Article

Bicalutamide Demonstrates Biologic Effectiveness in Prostate Cancer Cell Lines and Tumor Primary Cultures Irrespective of Her2/neu Expression LevelsLUCA GRAVINA, Giovanni; FESTUCCIA, Claudio; MILLIMAGGI, Danilo et al.Urology (Ridgewood, NJ). 2009, Vol 74, Num 2, pp 452-457, issn 0090-4295, 6 p.Article

Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressorsHODGSON, Myles C; ASTAPOVA, Inna; HOLLENBERG, Anthony N et al.Cancer research (Baltimore). 2007, Vol 67, Num 17, pp 8388-8395, issn 0008-5472, 8 p.Article

Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancerLUCA GRAVINA, Giovanni; FESTUCCIA, Claudio; PARADISO GALATIOTO, Giuseppe et al.Urology (Ridgewood, NJ). 2007, Vol 70, Num 4, pp 728-733, issn 0090-4295, 6 p.Article

Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mgSCATTONI, Vincenzo; MONTIRONI, Rodolfo; RIGATTI, Patrizio et al.BJU international (Papier). 2006, Vol 98, Num 1, pp 54-58, issn 1464-4096, 5 p.Article

The bicalutamide 150 mg early prostate cancer program : Findings of the North American trial at 7.7-year median followupMCLEOD, David G; SEE, William A; KLIMBERG, Ira et al.The Journal of urology. 2006, Vol 176, Num 1, pp 75-80, issn 0022-5347, 6 p.Article

Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancerBOCCARDO, Francesco; RUBAGOTTI, Alessandra; CONTI, Giario et al.Cancer chemotherapy and pharmacology. 2005, Vol 56, Num 4, pp 415-420, issn 0344-5704, 6 p.Article

4-OH tamoxifen does not interfere with bicalutamide inhibitory effects on human prostatic cancer cells in vitroBOCCARDO, F; MEDICINA, D; GALMOZZI, F et al.Anticancer research. 2005, Vol 25, Num 6B, pp 4277-4280, issn 0250-7005, 4 p.Article

Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancerSIEBER, Paul R; KEILLER, Danny L; KAHNOSKI, Richard J et al.The Journal of urology. 2004, Vol 171, Num 6, pp 2272-2276, issn 0022-5347, 5 p., 1Article

Gabapentin for hot flashes in prostate cancerJEFFERY, Sean M; PEPE, Jeffrey J; POPOVICH, Lisa M et al.The Annals of pharmacotherapy. 2002, Vol 36, Num 3, pp 433-436, issn 1060-0280Article

Bicalutamide: In early-stage prostate cancer. CommentariesCARSWELL, Christopher I; FIGGITT, David P; LO, Richard K et al.Drugs (Basel). 2002, Vol 62, Num 17, pp 2471-2481, issn 0012-6667, 11 p.Article

Effects of long-term treatment with the anti-androgen bicalutamide on human testis : an ultrastructural and morphometric studyMORGANTE, E; GRADINI, R; REALACCI, M et al.Histopathology. 2001, Vol 38, Num 3, pp 195-201, issn 0309-0167Article

The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade : A double blind, randomized, placebo-controlled crossover studyDIAMOND, Terrence H; WINTERS, Julle; SMITH, Angie et al.Cancer. 2001, Vol 92, Num 6, pp 1444-1450, issn 0008-543XArticle

Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model systemCULIG, Z; HOFFMANN, J; KLOCKER, H et al.British journal of cancer. 1999, Vol 81, Num 2, pp 242-251, issn 0007-0920Article

Enzyme-inducing effects of bicalutamide in mouse, rat and dogMCKILLOP, D; BUTTERS, C. J; HILL, S. J et al.Xenobiotica (London. Print). 1998, Vol 28, Num 5, pp 465-478, issn 0049-8254Article

Casodex^tm 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer : An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studiesTYRRELL, C. J; DENIS, L; NEWLING, D et al.European urology. 1998, Vol 33, Num 1, pp 39-53, issn 0302-2838Article

Antiandrogen monotherapy in the management of advanced prostate cancerKAISARY, A. V.European urology. 1997, Vol 31, pp 14-19, issn 0302-2838, SUP2Conference Paper